Last reviewed · How we verify
IMP Application KM-001
At a glance
| Generic name | IMP Application KM-001 |
|---|---|
| Also known as | Experimental drug administration |
| Sponsor | Kamari Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC (PHASE1)
- Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases (PHASE1)
- KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMP Application KM-001 CI brief — competitive landscape report
- IMP Application KM-001 updates RSS · CI watch RSS
- Kamari Pharma Ltd portfolio CI